Physician profile
Beverly Carter
NPI 1558969253
$2,207.47
in general payments reported to CMS, 2019-2025
11 companies · $824 in 2025
The $824 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $65.38 · 2023: $15.63 · 2024: $1,302 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $1,306.12 | 2024-2025 | Daxxify |
| Lilly USA, LLC | $285.32 | 2022-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $149.32 | 2024-2025 | Ozempic |
| Teva Pharmaceuticals USA, INC. | $137.17 | 2024 | Austedo Xr, Ajovy |
| Astrazeneca Pharmaceuticals LP | $121.84 | 2025 | Tezspire |
| Exact Sciences Corporation | $71.92 | 2024-2025 | Cologuard Collection Kit |
| Sun Pharmaceutical Industries INC. | $63.91 | 2025 | |
| Organon LLC | $21.38 | 2025 | Nexplanon |
| Abbvie INC. | $18.60 | 2025 | |
| Pfizer INC. | $17.52 | 2024 | |
| Phathom Pharmaceuticals, INC. | $14.37 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.